PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8199383

Endocarditis.

S J Hutchison·P A Chandraratna
View original source ↗Export metadata ↓

Abstract

The continuing medical literature attests to the fact that infective endocarditis is a serious and complex disease, which in many populations continues to occur at an incidence of approximately 20 per 100,000, and carries a 5% to 40% mortality, depending on numerous pathogen and patient factors. Clinical investigation continues along several lines, including analysis of the clinical utility of diagnostic imaging, especially the contribution of transthoracic and transesophageal echocardiography (and, conversely, the risk of endocarditis from transesophageal imaging). Epidemiological and cohort descriptive studies give insight into the underlying causes of the disease, and risk factors for poor outcome, from which guidelines for management can be surmised.

Explore related subjects

Cross InfectionEchocardiography, TransesophagealEndocarditis, BacterialHeart Valve DiseasesHeart Valve ProsthesisHemodynamicsHumansPostoperative ComplicationsReoperationRisk FactorsJournal ArticleResearch Support, Non-U.S. Gov'tReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S J Hutchison, P A Chandraratna. 1994. Endocarditis.. https://doi.org/10.1097/00001573-199403000-00006

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates.

OBJECTIVE: We carried out a randomized placebo-controlled trial in very low birth weight neonates (VLBWNs), comparing the incidence of nosocomial infections after the prophylactic use of recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) versus placebo in VLBWNs. STUDY DESIGN: VLBWNs (n = 264), weighing 501 to 1000 g, </=72 hours of age were randomly assigned to receive rhu GM-CSF (8 microg/kg/d), administered intravenously (n = 134) over 2 hours daily x 7 days and every other day for 21 days, or placebo (n = 130). The safety, incidence of nosocomial infections, days of absolute neutrophil count >/=4000/mm,3 peripheral blood progenitor studies, and 24-hour polymorphonuclear leukocyte C3bi receptor expression were compared between the 2 treatment groups. RESULTS: No (grade III/IV) toxicity or adverse events were associated with rhu GM-CSF. The absolute neutrophil count and absolute eosinophil count were significantly elevated in the rhu GM-CSF group on days 7 (P =.001), 14 (P =.001), and 21 (P =.007) and on days 7 and 28 (P =.012 and P =.001, respectively). However, there was no difference in the incidence of confirmed nosocomial infections between the 2 treatment groups in this trial (40% vs 39%, rhu GM-CSF vs placebo; P = NS). CONCLUSION: In a large randomized placebo-controlled trial, prophylactic administration of rhu GM-CSF in VLBWNs does not appear to decrease the incidence of nosocomial infections.

Cross Infection↗
PubMed1998

[Emergence of new-risk factors associated with nosocominal infection].

During the last several decades, we have experienced the emerging and reemerging of infectious pathogens and diseases. The outbreaks of infection due to these pathogens sometimes occur via the sources and/or routes which have not been recognized during previous studies on epidemiology and pathogenesis of the diseases. There are many factors contributing to the increase in infectious diseases. Namely, medical progress often results in an increasing number of immunocompromised patients. Common, usually avirulent, commensal and environmental organisms become pathogens to these patients. The evolution of organisms acquiring resistance to antimicrobial agents, disinfectants, and environmental stimuli also relates to the high incidence of nosocominal (hospital-acquired) infections as well as to the clinical situation of the patients. Because of these tendencies, as risks of nosocominal infections, are characteristic especially in major health care centers such as large teaching hospitals, most health care workers are obliged to participate actively in control and preventive efforts in addition to their traditional roles. In this review I discuss the recent characteristics of nosocominal pathogens and the environments surrounding the hospitalized patients to design effective strategies for and to facilitate the infection control activities.

Cross Infection↗
PubMed1998

[Spread of methicillin-resistant Staphylococcus aureus. Are our hygienic precautions sufficient?].

A patient was transferred from Pakistan to a Danish orthopaedic ward. In Denmark he was tested MRSA-positive. Two months after he was discharged, similar MRSA strains were found in another patient. The two patients had been on the same ward for one week. All hygienic precautions had been taken. Staff and other patients on the ward at the relevant time all tested MRSA-negative.

Cross Infection↗